NCT06846684

A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects

A Phase 1, Open-label, Fixed-sequence, Drug-drug Interaction Study to Investigate the Effect of Single and Multiple Oral Doses of SB17170 on the Pharmacokinetics of SB_MDZ in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: SPARK Biopharma · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This clinical trial is a phase 1, open-label, fixed-sequence, drug-drug interaction study to investigate the effect of single and multiple oral doses of SB17170 on the pharmacokinetics of SB\_MDZ in healthy adult subjects.

Conditions

• Drug Drug Interaction (DDI)

Interventions

Type	Name	Description
DRUG	SB17170	PO, QD
DRUG	SB_MDZ	IV

Timeline

• Start date: 2025-03-27
• Primary completion: 2025-06-10
• Completion: 2025-09-12
• First posted: 2025-02-26
• Last updated: 2025-11-19

Locations

1 site across 1 country: South Korea